Development of a dendritic cell vaccine encoding multiple cytotoxic T lymphocyte epitopes targeting hepatitis C virus

International Journal of Molecular Medicine

Volumn 32, Issue 4, 2013, Pages 901-909

  Zhou, Yun ^a   Zhao, Futao ^a   Chen, Lin ^a   Ma, Li ^a   Wang, Yu ^a   He, Yu ^a   Ma, Zhiyuan ^a   Liu, Haili ^a   Guo, Yonghong ^a   Zhang, Ying ^a   Yao, Zhiqiang ^b   Hao, Chunqiu ^a   Jia, Zhansheng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b East Tennessee State University   (United States)

Author keywords

Adenovirus; Cytotoxic T lymphocyte epitope; Dendritic cell; Hepatitis C virus; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 12P70; NONSTRUCTURAL PROTEIN 4B; T LYMPHOCYTE ANTIGEN;

ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG DESIGN; FLOW CYTOMETRY; HEPATITIS C VIRUS; HEPATOMA CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOVIRIDAE; CELL LINE, TUMOR; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HEPACIVIRUS; HUMANS; INTERFERON-GAMMA; PHENOTYPE; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VIRAL HEPATITIS VACCINES;

EID: 84883340742     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1466     Document Type: Article

References (45)

1. Shepard CW, Finelli L and Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567, 2005.
2. Manns MP, Wedemeyer H and Cornberg M: Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55: 1350-1359, 2006.
3. Moreno C and Deltenre P: Management of chronic hepatitis C in 2012 in Belgium. Rev Med Brux 33: 223-227, 2012 (In French).
4. Yu CI and Chiang BL: A new insight into hepatitis C vaccine development. J Biomed Biotechnol 2010: 548280, 2010.
5. Tang HL and Grisé H: Cellular and molecular biology of HCV infection and hepatitis. Clin Sci (Lond) 117: 49-65, 2009.
6. Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB and Baumert TF: Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 8: 333-345, 2009.
7. Dazert E, Neumann-Haefelin C, Bressanelli S, Fitzmaurice K, Kort J, Timm J, McKiernan S, Kelleher D, Gruener N, Tavis JE, Rosen HR, Shaw J, Bowness P, Blum HE, Klenerman P, Bartenschlager R and Thimme R: Loss of viral fitness and cross- recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest 119: 376-386, 2009.
8. Bain C, Fatmi A, Zoulim F, Zarski JP, Trépo C and Inchauspé G: Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120: 512-524, 2001.
9. Ciesek S, Liermann H, Hadem J, Greten T, Tillmann HL, Cornberg M, Aslan N, Manns MP and Wedemeyer H: Impaired TRAIL-dependent cytotoxicity of CD1c positive dendritic cells in chronic hepatitis C virus infection. J Viral Hepat 15: 200-211, 2008.
10. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H and Rehermann B: Impaired effector function of hepatitis C virus specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169: 3447-3458, 2002.
11. Steinman RM and Banchereau J: Taking dendritic cells into medicine. Nature 449: 419-426, 2007.
12. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K and Bonehill A: Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 56: 1513-1537, 2007.
13. Lundqvist A, Noffz G, Pavlenko M, Saebøe-Larssen S, Fong T, Maitland N and Pisa P: Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection. J Immunother 25: 445-454, 2002.
14. Dietz AB and Vuk Pavlovic S: High efficiency adenovirus mediated gene transfer to human dendritic cells. Blood 91: 392-398, 1998.
15. Li D, Xie YW, Xue XP, Bai XF and Jia ZS: Forecasting of hepatitis C virus CTL epitopes and design of multi-epitopes vaccine. Zhonghua Gan Zang Bing Za Zhi 17: 786-787, 2009. (In Chinese).
16. Duan L, Lei P, Yumei X, Xiaoping X, Futao Z, Li M, Xin W, Jiuping W, Xuefan B and Zhansheng J: Prediction and identification of Chinese hepatitis C viral specific cytotoxic T lymphocyte epitopes. J Med Virol 83: 1315-1320, 2011.
17. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, Sette A and Pape GR: Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71: 6011-6019, 1997.
18. Wang QM, Sun SH, Hu ZL, Zhou FJ, Yin M, Xiao CJ and Zhang JC: Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine. Scand J Immunol 60: 219-225, 2004.
19. Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, Fowler P, Houghton M and Chisari FV: Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 95: 521-530, 1995.
20. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, Vogelstein B and He TC: A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2: 1236-1247, 2007.
21. Pham L, Ye H, Cosset FL, Russell SJ and Peng KW: Concentration of viral vectors by co-precipitation with calcium phosphate. J Gene Med 3: 188-194, 2001.
22. Mittereder N, March KL and Trapnell BC: Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70: 7498-7509, 1996.
23. English D and Andersen BR: Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods 5: 249-252, 1974.
24. Babatz J, Röllig C, Oelschlägel U, Zhao S, Ehninger G, Schmitz M and Bornhäuser M: Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res 12: 515-523, 2003.
25. Timares L, Douglas JT, Tillman BW, Krasnykh V and Curiel DT: Adenovirus-mediated gene delivery to dendritic cells. Methods Mol Biol 246: 139-153, 2004.
26. Wang L, Wang ZH, Shen CY, You ML, Xiao JF and Chen GQ: Differentiation of human bone marrow mesenchymal stem cells grown in terpolyesters of 3-hydroxyalkanoates scaffolds into nerve cells. Biomaterials 31: 1691-1698, 2010.
27. Ma L, Wei X, Zhang Y, Wang PZ, Lian JQ and Jia ZS: Observation of chimeric hepatitis C virus in infected Huh7.5 cell through transmission electron microscopy. Chin J Microbiol Immunol 29: 568-573, 2009.
28. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA and Rice CM: Complete replication of hepatitis C virus in cell culture. Science 309: 623-626, 2005.
29. Brand K, Klocke R, Possling A, Paul D and Strauss M: Induction of apoptosis and G2/M arrest by infection with replication- deficient adenovirus at high multiplicity of infection. Gene Ther 6: 1054-1063, 1999.
30. Figdor CG, de Vries IJ, Lesterhuis WJ and Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med 10: 475-480, 2004.
31. Vorburger SA and Hunt KK: Adenoviral gene therapy. Oncologist 7: 46-59, 2002.
32. Lasaro MO and Ertl HC: New insights on adenovirus as vaccine vectors. Mol Ther 17: 1333-1339, 2009.
33. Liu J, Cao S, Kim S, Chung EY, Homma Y, Guan X, Jimenez V and Ma X: Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression. Curr Immunol Rev 1: 119-137, 2005.
34. Gattoni A, Parlato A, Vangieri B, Bresciani M and Derna R: Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts). Clin Ter 157: 457-468, 2006.
35. Yanagi M, Purcell RH, Emerson SU and Bukh J: Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 262: 250-263, 1999.
36. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH and Chisari FV: Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 99: 15661-15668, 2002.
37. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC and Chisari FV: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194: 1395-1406, 2001.
38. Liu C, Zhu H, Tu Z, Xu YL and Nelson DR: CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity. Hepatology 37: 1335-1342, 2003.
39. Jo J, Aichele U, Kersting N, Klein R, Aichele P, Bisse E, Sewell AK, Blum HE, Bartenschlager R, Lohmann V and Thimme R: Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136: 1391-1401, 2009.
40. Bowen DG and Walker CM: Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946-952, 2005.
41. Frese M, Schwärzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O and Bartenschlager R: Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35: 694-703, 2002.
42. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J and Manns MP: Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134: 1385-1395, 2008.
43. Alvarez-Lajonchere L, Shoukry NH, Grá B, Amador- Cañizares Y, Helle F, Bédard N, Guerra I, Drouin C, Dubuisson J, González-Horta EE, Martínez G, Marante J, Cinza Z, Castellanos M and Dueñas-Carrera S: Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 16: 156-167, 2009.
44. Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, Eriksson EM, Chin R, Li S, Wall DM, Sparrow RL, Moloney J, Loudovaris M, Ffrench R, Prince HM, Hart D, Zeng W, Torresi J, Brown LE and Jackson DC: A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 53: 599-607, 2010.
45. Zhou Y, Zhang Y, Yao ZQ, Moorman JP and Jia ZS: Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology 136: 385-396, 2012.